What is the level of liabilities of Vertex Pharmaceuticals this year?
Vertex Pharmaceuticals has a debt balance of 5.15 B USD this year.
In 2024, Vertex Pharmaceuticals's total liabilities amounted to 5.15 B USD, a 21.51% difference from the 4.24 B USD total liabilities in the previous year.
In the annual report of the Vertex Pharmaceuticals share (US92532F1003, 882807, VRTX), it breaks down its revenues into 4 segments: 1. Symdeko, 2. Orkambi, 3. Kalydeco, 4. Trikafta. The Vertex Pharmaceuticals stock (WKN: 882807, ISIN: US92532F1003, Ticker Symbol: VRTX) is a leading investment for investors interested in participating in the Health Care sector.
Vertex Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vertex Pharmaceuticals's financial stability, operational efficiency, and long-term viability.
By comparing Vertex Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Vertex Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Vertex Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Vertex Pharmaceuticals has a debt balance of 5.15 B USD this year.
The liabilities of Vertex Pharmaceuticals have increased by 21.51% increased compared to the previous year.
High liabilities can pose a risk for investors of Vertex Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Vertex Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Vertex Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Vertex Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Vertex Pharmaceuticals include investments, acquisitions, operating costs, and sales development.
The liabilities of Vertex Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Vertex Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.
The current dividend yield of Vertex Pharmaceuticals is .
Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
Vertex Pharmaceuticals paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Vertex Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of Vertex Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
The last dividend was paid out on 10/5/2024.
In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.
The dividends of Vertex Pharmaceuticals are distributed in USD.
The Vertex Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.